Immune Diagnostics is an industry leader in Streptococcus pneumoniae microbiology and related analytics. We provide analytical tools and services to vaccine developers, public health organizations, and researchers dedicated to reducing global morbidity and mortality from pneumococcal pneumonia and related diseases. These are largely preventable diseases that have been reduced in developed countries by use of effective vaccine programs.
Our leading products include fully human monoclonal antibodies against pneumococcal capsular polysaccharide serotypes, for which we hold the worldwide exclusive license. Immune Diagnostics is currently developing a broad range of reagents, standards and controls to improve vaccine and drug development, manufacturing quality control and a range of other applications. We also offer custom high-throughput serotyping assays. The serotyping technology is used to generate pneumococcal carriage data across large populations to identify the most prevalent pathogens being carried. This data is essential to developing and deploying the most effective vaccines.